TCM-based therapy for coronary disorders - China Pharma Holdings

Drug Profile

TCM-based therapy for coronary disorders - China Pharma Holdings

Alternative Names: TCM for coronary heart disease - China Pharma Holdings; Traditional Chinese Medicine - China Pharma Holdings

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator China Pharma Holdings
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Coronary disorders

Most Recent Events

  • 01 Apr 2016 China Pharma Holdings completes a phase III trial in Coronary disorders in China
  • 15 Mar 2012 Phase-III clinical trials in Coronary disorders in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top